Key Highlights
- Moleculin Biotech priced a best-efforts public offering of 12,376,667 shares at 0.75 dollars per share.
- The offering includes warrants to purchase up to 37,130,001 additional shares of common stock.
- The offering is expected to close on or about August 3, 2026.
- Net proceeds are intended to advance Annamycin through clinical development and for Working Capital .
A Dilutive Raise to Fund Continued Clinical Development
Moleculin Biotech ( Nasdaq :MBRX) announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock, or pre-funded warrants in lieu thereof, along with warrants to purchase up to 37,130,001 shares of common stock, at a combined public offering price of $0.75 per share and associated warrants. The common warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date.
The offering is expected to close on or about August 3, 2026, subject to satisfaction of customary closing conditions. The company intends to use the net proceeds to advance Annamycin through clinical development and for working capital, with Roth Capital Partners acting as exclusive Placement agent and Maxim Group LLC serving as Financial Advisor to the company.
Proceeds Aimed at Advancing a Pivotal AML Trial
Moleculin is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard to treat tumors and viruses. The company's lead program, Annamycin, is a next generation anthracycline designed to avoid multidrug resistance mechanisms and lack the cardiotoxicity common with currently prescribed anthracyclines, currently in development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company has begun the MIRACLE trial, a pivotal adaptive design Phase 2/3 study evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia. Following a successful earlier Phase 1B/2 study and input from the FDA and the EMA, the company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin in AML, though the study remains subject to future regulatory filings and potential additional feedback. Beyond Annamycin, Moleculin's pipeline includes WP1066, targeting brain, pancreatic, and other cancers, and a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications.
Balancing Near Term Dilution Against Extended Clinical Runway
The offering's structure, combining common stock with a substantial Warrant component covering more than 37 million additional shares, introduces meaningful potential dilution for existing shareholders beyond the initial share count if the warrants are exercised over their five year term. For a clinical stage company without approved products generating Revenue , such capital raises are a common mechanism to fund the extended and capital intensive process of advancing a pivotal trial like MIRACLE toward potential regulatory approval.
Should the MIRACLE trial continue to progress following the de-risking steps already taken with FDA and EMA input, the additional capital could provide the runway needed to reach key clinical milestones. However, the pricing of the offering at $0.75 per share, combined with the scale of the associated warrant issuance, reflects the challenging Capital Markets environment many small cap clinical stage biotechs continue to face when raising funds ahead of pivotal trial readouts.
Conclusion
Moleculin's $9.3 million public offering reflects the ongoing capital needs of a clinical stage biopharmaceutical company advancing a pivotal trial for a novel AML treatment candidate. Whether the additional funding proves sufficient to carry Annamycin through the MIRACLE trial toward a potential regulatory filing may depend on the pace of enrollment and clinical progress in the coming quarters. The scale of the associated Warrant Coverage suggests investors should Factor in potential further dilution as the company continues funding its clinical development pipeline.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...